Dublin, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The "Diamyd Emerging Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering. A pioneering analysis of Diamyd, an ...
STOCKHOLM--(BUSINESS WIRE)-- Quarterly Report Diamyd Medical AB (publ)(STO:DIAMB)(Pink Sheets:DMYDY), fiscal year 2011/2012 (www.omxgroup.com ticker: DIAM B; www.otcqx.com ticker: DMYDY) Reporting ...
Diamyd Medical has announced that the independent Data Safety Monitoring Board (DSMB) recommended the continuation of the Phase III DIAGNODE-3 trial of Diamyd for type 1 diabetes (T1D) without ...
STOCKHOLM--(BUSINESS WIRE)-- Regulatory News: Diamyd Medical AB has entered into an agreement for the sale of the U.S. subsidiary, Diamyd, Inc., involved in drug development primarily relating to the ...
Historically, there has never even been a glimmer of hope for stopping the autoimmune condition type 1 diabetes (T1D) in its tracks. But now, Swedish biotech company Diamyd Medical is moving forward ...
Diamyd Medical AB announced that it has suspended and is initiating the closure of its U.S. Phase 3 study, DiaPrevent, which was evaluating the use of Diamyd for the treatment of newly diagnosed type ...
(RTTNews) - Diamyd Medical announced that it has reached alignment with the U.S. Food and Drug Administration to accelerate the primary efficacy readout in its ongoing pivotal, registrational Phase 3 ...
Diamyd is an antigen-specific immunotherapy intended to preserve endogenous insulin production. The Food and Drug Administration (FDA) has granted Fast Track designation to Diamyd ® (recombinant human ...
STOCKHOLM, April 21, 2025 /PRNewswire/ -- In a recent investor interview, Diamyd Medical Board Member Professor Mark Atkinson and CEO Ulf Hannelius shared key insights into the Company's positioning ...
Diamyd Medical (Nasdaq Stockholm First North Ticker: DMYD B) informs that the Company has accepted an offer from a group of international institutional investors, previously not shareholders in Diamyd ...
Diamyd Medical (NASDAQ OMX First North, Ticker: DMYD B) informs that the ongoing combination study DIABGAD has been awarded EUR 120 000, corresponding to about SEK 1.1 million, in EU-funding. The ...
The European Central Bank on Friday endorsed the European Commission’s plan to better integrate EU capital markets through joint supervision, but cautioned the move needed to be adequately staffed and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results